These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 30679156)
1. A Synthetic DNA, Multi-Neoantigen Vaccine Drives Predominately MHC Class I CD8 Duperret EK; Perales-Puchalt A; Stoltz R; G H H; Mandloi N; Barlow J; Chaudhuri A; Sardesai NY; Weiner DB Cancer Immunol Res; 2019 Feb; 7(2):174-182. PubMed ID: 30679156 [TBL] [Abstract][Full Text] [Related]
2. Neoantigen-specific cytotoxic Tr1 CD4 T cells suppress cancer immunotherapy. Sultan H; Takeuchi Y; Ward JP; Sharma N; Liu TT; Sukhov V; Firulyova M; Song Y; Ameh S; Brioschi S; Khantakova D; Arthur CD; White JM; Kohlmiller H; Salazar AM; Burns R; Costa HA; Moynihan KD; Yeung YA; Djuretic I; Schumacher TN; Sheehan KCF; Colonna M; Allison JP; Murphy KM; Artyomov MN; Schreiber RD Nature; 2024 Aug; 632(8023):182-191. PubMed ID: 39048822 [TBL] [Abstract][Full Text] [Related]
3. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170 [TBL] [Abstract][Full Text] [Related]
4. Neoleukin-2 enhances anti-tumour immunity downstream of peptide vaccination targeted by an anti-MHC class II VHH. Crowley SJ; Bruck PT; Bhuiyan MA; Mitchell-Gears A; Walsh MJ; Zhangxu K; Ali LR; Jeong HJ; Ingram JR; Knipe DM; Ploegh HL; Dougan M; Dougan SK Open Biol; 2020 Feb; 10(2):190235. PubMed ID: 32019478 [TBL] [Abstract][Full Text] [Related]
5. Machine-Learning Prediction of Tumor Antigen Immunogenicity in the Selection of Therapeutic Epitopes. Smith CC; Chai S; Washington AR; Lee SJ; Landoni E; Field K; Garness J; Bixby LM; Selitsky SR; Parker JS; Savoldo B; Serody JS; Vincent BG Cancer Immunol Res; 2019 Oct; 7(10):1591-1604. PubMed ID: 31515258 [TBL] [Abstract][Full Text] [Related]
6. Harnessing neoantigen specific CD4 T cells for cancer immunotherapy. Brightman SE; Naradikian MS; Miller AM; Schoenberger SP J Leukoc Biol; 2020 Apr; 107(4):625-633. PubMed ID: 32170883 [TBL] [Abstract][Full Text] [Related]
11. Generation of multiepitope cancer vaccines based on large combinatorial libraries of survivin-derived mutant epitopes. Domínguez-Romero AN; Martínez-Cortés F; Munguía ME; Odales J; Gevorkian G; Manoutcharian K Immunology; 2020 Oct; 161(2):123-138. PubMed ID: 32619293 [TBL] [Abstract][Full Text] [Related]
12. CD4 T cell-activating neoantigens enhance personalized cancer vaccine efficacy. Huff AL; Longway G; Mitchell JT; Andaloori L; Davis-Marcisak E; Chen F; Lyman MR; Wang R; Mathew J; Barrett B; Rahman S; Leatherman J; Yarchoan M; Azad NS; Yegnasubramanian S; Kagohara LT; Fertig EJ; Jaffee EM; Armstrong TD; Zaidi N JCI Insight; 2023 Dec; 8(23):. PubMed ID: 38063199 [TBL] [Abstract][Full Text] [Related]
13. Co-expression of immunogenic determinants by the same cellular immunogen is required for the optimum immunotherapeutic benefit in mice with melanoma. Xu W; de Zoeten E; Carr-Brendel V; Cohen EP Cancer Immunol Immunother; 1998 Jan; 45(5):217-24. PubMed ID: 9439644 [TBL] [Abstract][Full Text] [Related]
14. Self-assembled nanoparticles based on DNA origami and a nitrated T helper cell epitope as a platform for the development of personalized cancer vaccines. Kang Y; Zhang W; Yu Q; Gao L; Quan J; Gu F; Wu Y; Tian Y; Wu Z; Shao S; Zhou H; Duan S; Zhou Y; Zhang L; Gao X; Tian H; Yao W Cancer Immunol Immunother; 2023 Aug; 72(8):2741-2755. PubMed ID: 37119260 [TBL] [Abstract][Full Text] [Related]
15. Dose escalation study of a personalized peptide-based neoantigen vaccine (EVX-01) in patients with metastatic melanoma. Mørk SK; Skadborg SK; Albieri B; Draghi A; Bol K; Kadivar M; Westergaard MCW; Stoltenborg Granhøj J; Borch A; Petersen NV; Thuesen N; Rasmussen IS; Andreasen LV; Dohn RB; Yde CW; Noergaard N; Lorentzen T; Soerensen AB; Kleine-Kohlbrecher D; Jespersen A; Christensen D; Kringelum J; Donia M; Hadrup SR; Marie Svane I J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38782542 [TBL] [Abstract][Full Text] [Related]
16. Neo-intline: integrated pipeline enables neoantigen design through the in-silico presentation of T-cell epitope. Li B; Jing P; Zheng G; Pi C; Zhang L; Yin Z; Xu L; Qiu J; Gu H; Qiu T; Fang J Signal Transduct Target Ther; 2023 Oct; 8(1):397. PubMed ID: 37848417 [TBL] [Abstract][Full Text] [Related]
17. Elicitation of T cell responses to histologically unrelated tumors by immunization with the novel cancer-testis antigen, brother of the regulator of imprinted sites. Ghochikyan A; Mkrtichyan M; Loukinov D; Mamikonyan G; Pack SD; Movsesyan N; Ichim TE; Cribbs DH; Lobanenkov VV; Agadjanyan MG J Immunol; 2007 Jan; 178(1):566-73. PubMed ID: 17182597 [TBL] [Abstract][Full Text] [Related]
18. Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunity. Liu L; Chen J; Zhang H; Ye J; Moore C; Lu C; Fang Y; Fu YX; Li B Nat Cancer; 2022 Apr; 3(4):437-452. PubMed ID: 35393580 [TBL] [Abstract][Full Text] [Related]